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Abstract Use of PET/MR in children has not previously been
reported, to the best of our knowledge. Children with systemic
malignancies may benefit from the reduced radiation exposure
offered by PET/MR. We report our initial experience with PET/
MR hybrid imaging and our current established sequence pro-
tocol after 21 PET/MR studies in 15 children with multifocal
malignant diseases. The effective dose of a PET/MR scan was
only about 20% that of the equivalent PET/CT examination.
Simultaneous acquisition of PET and MR data combines the
advantages of the two previously separate modalities. Further-
more, the technique also enables whole-body diffusion-
weighted imaging (DWI) and statements to be made about the
biological cellularity and nuclear/cytoplasmic ratio of tumours.
Combined PET/MR saves time and resources. One disadvan-
tage of PET/MR is that in order to have an effect, a significantly
longer examination time is needed than with PET/CT. In our
initial experience, PET/MRhas turned out to be an unexpectedly
stable and reliable hybrid imaging modality, which generates a
complementary diagnostic study of great additional value.
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Introduction
Whole-body PET/MR scanners are currently available from two
companies and have been in clinical use since 2010: the GEM-
INI TF PET/MR imaging system (Philips Medical Systems,
Eindhoven, The Netherlands) and the Biograph mMR
(Siemens, Erlangen, Germany). The technical solution and phi-
losophy between the two scanners are different. With the Gem-
ini TF PET/MR scanner, the PET and MR scans are carried out
in quick succession in the same room and on the same moving
table, but on two different devices. ThemMR scanner is the first
available fully integrated whole-body PET/MR system.
It should be emphasized that up to September 2011 both
devices were used exclusively for research, and were optimized
in research units with the help of the developers and manufac-
turers, and with the guidance of physicians with regard to their
clinical needs. The first regular CE-certified device for clinical
use was installed in 2011 at the University Hospital of Leipzig,
Germany [1, 2]. Under the auspices of the Department of
Nuclear Medicine, the various partners are in the process of
carrying out both clinical research projects and examinations.
PET/CT imaging is widely used even in paediatric oncol-
ogy. Switching from PET/CT to PET/MR would reduce the
radiation exposure caused by the CT part of the examination.
This is one of the most important aspects for those who have
supported the establishment and application of PET/MR in
children [3, 4]. Since November 2011, all examinations con-
ducted in children with oncological problems requiring
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whole-body hybrid imaging in our institution have been per-
formed exclusively using PET/MR (21 examinations). To
date, no imaging protocols or information about the feasibility
of whole-body PET/MR in children have been published. The
aim of this report was to share our initial experience with this
innovative technique.
Imaging technique
The basic idea of combining all the advantages of PET with
those of MR in only one examination has been realized by
two manufacturers using two very different solutions. The
older configuration (Philips) connects two devices consec-
utively. The patient is examined on the same examination
table by time-delayed MR and PET, and the analysed data
are then merged. The advantage of using this method is that
any interference or crosstalk between PET and MR is easier
to avoid. However, with this tandem configuration, simul-
taneous data acquisition from both modalities is not possi-
ble. The newer alternative setup is an integrated whole-body
PET/MR system (Siemens). The advantage of this technical
solution is that the acquisition of PET and MR data syn-
chronously allows true simultaneous registration of morpho-
logical and metabolic processes that follow the same
timeline, and results in a significantly improved coregistra-
tion of the two modalities [5]. In addition, the simultaneous
acquisition of data generates results in a shorter examination
time and therefore results in higher patient throughput, as
shown by von Schulthess and Burger [6]. Shorter examina-
tion times for evaluating treatment response in children are,
in particular, highly relevant in clinical practice.
The setup of the fully integrated whole-body PET/MR
system we use for our investigations corresponds to the outer
structure of the equivalent commercial 3-T unit. The PET
detector ring is integrated between the patient-oriented radio-
frequency body coil and the gradient coil. Other coils, e.g. the
main magnetic coils, are arranged as in other MR machines in
the cooled area of the outer mMR [7]. To ensure compatibility
between the two devices, and to create as little interference or
crosstalk as possible between the MR and PET units, the
patient-oriented RF coils, the RF body coil and the PET
detectors were designed from scratch. In practice, in compar-
ison to a comparable conventional 3-T system (Trio; Siemens,
Germany), any alteration of the MR signal is not noticeable.
Identical sequence parameters can be selected for both units.
The sequences and parameters are reproducible from the 3-T
equipment and are, therefore, very easy to transfer. As a result,
the established standard diagnostic MR protocol can, in prin-
ciple, be carried out completely on the mMR system. Even in
young children, 3-T MR devices, compared to 1.5-T devices,
have been very successful. The smaller body diameter in
children in the abdominal and thoracic areas means that the
typical 3-T signal loss artefacts seen in adults are less prob-
lematic, and the high field strength leads to less time required
for the investigation.
For PET data acquisition, newly developed detectors are
used (avalanche photodiodes, APD) whose performance does
not suffer from the influence of the magnetic field. These
diodes have a size of 5×5 mm. Typically, a whole-body
measurement using PET/MR is performed in children in seven
sections of 30 cm each. With overlapping areas, this results in
a maximal total length of about 160 cm. The MR data acqui-
sition lasts 5.5 min per section and consists of two T2 turbo
inversion recovery magnitude (TIRM) sequences—transverse
and coronal—and a transverse diffusion-weighted sequence.
The PET acquisition time is adapted to the measurement time
of the MR examination. This does not lead to prolongation of
data acquisition. An additional measurement time must be
allowed for the measurement and calculation of the attenua-
tion correction for PET and for the “shimming” of the mag-
netic field [8]. The necessary PET attenuation correction is
carried out per section with a MR Dixon sequence consisting
of four individual measurements (water image, fat image, and
in-phase and opposed-phase T1 images) from which a μ-map
is generated (Fig. 1) [9, 10]. This μ-map is then utilized for
attenuation correction of the PET data.
In PET/MR, the radiation exposure is from the PET
component and is 3–4 mSv in 3-D mode [11, 12]. In con-
trast, in diagnostic PET/CT, the typical effective dose for a
child is about 25 mSv (range: 6.2 to 60.7 mSv). The addi-
tional dose fraction with whole-body CT is highly depen-
dent on the selected imaging protocol and thus exposure
parameters, and is on average 20 mSv (range: 2.7 to
54.2 mSv). Therefore, it is likely that the radiation exposure
from a PET/MR scan is 80% less than that from a PET/CT
scan. It is also important to consider that children with
oncological diseases often require multiple hybrid imaging
studies (mean: 3.2 studies, range: 1–14) [13].
Imaging protocols
Due to the novelty of the integrated PET/MR system, no
recommendation for an imaging protocol in children has yet
been published. We therefore developed a child-specific
sequence protocol based on our experience with whole-
body MR in children at 1.5 and 3 T and paediatric PET/
CT [11, 14]. In establishing our investigation strategy, we
pursued three premises that appeared to us to be absolutely
necessary for a PET/MR diagnostic procedure:
1. Hybrid PET/MR imaging should not lead to diagnostic
degradation in either the MR or PET imaging. The
anatomical information, which is of particular impor-
tance for the paediatric surgeon, must be maintained
without any modifications or restrictions.
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2. The time for a whole-body examination should be ac-
ceptable to the child (45 to 60 min).
3. PET and MR should not just be performed for additive
benefit, but should also offer a new, complementary
diagnostic quality and clear diagnostic profit.
To achieve these partly contradictory objectives, a com-
promise was necessary that had to be found in collaboration
with clinical colleagues (paediatric surgeons, paediatri-
cians), nuclear medicine physicians and paediatric radiolog-
ists. In particular, a numerical and temporal limitation of the
MR sequences was necessary, but without reducing the
diagnostic safety for the child [15]. The increased field
strength of 3 T was used to reduce the time required for
the sequences. A simultaneous gain in image quality, com-
pared to 1.5 T, is currently not possible or aimed for.
Our PET/MR protocol is performed as a complementary
combination of whole-body imaging to determine the spread
of the cancer and includes additional regional MR imaging
to give more detailed visualization for surgical procedures
[16]. Supplementing the whole-body examination, these
additional sequences allow a more dedicated local investi-
gation of the tumour when necessary. The anatomical
coverage of the whole-body MR scan is variable; the max-
imum measurable length in the mMR system is 160 cm. If
required, the lower legs and feet can be investigated sepa-
rately in a second step after repositioning.
Our current sequence concept includes the following
sequences:
1. Water-sensitive fast inversion recovery sequence (e.g.
TIRM): coronal, 5-mm slice thickness; transverse, 4.5-
mm slice thickness (for details, see Table 1). The tho-
racic and upper abdominal sections are acquired with
respiratory triggering using a breathing belt.
2. Whole-body diffusion-weighted imaging at a slice
thickness of 4.5 mm and for calculation of the ADC
(B-value 800 s/mm2) [17].
3. Further, dedicated sequences are performed depending
on the problem; the following supplementary sequences
are typically used depending on the region:
– T1-weighted spin echo with fat saturation after con-
trast agent administration as a transverse whole-body
examination
– Head: T2-weighted FLAIR, transverse
Fig. 1 Two-point volume interpolated breathhold examination (VIBE)
Dixon sequence for determination/segmentation of fat, lung tissue, air
and water (soft tissue) and assignment of a map of linear attenuation
coefficients (μ-map). All four components of the sequence are required
for calculating an attenuation correction pattern (μ-map) for the PET
data: in-phase and opposed-phase T1 images (a, b), and fat image and
water image (c, d). From these images, the μ-map that is utilized for
attenuation correction of the PET data is generated/segmented (e). For
the subsequent PET/MR fusion, only the attenuation-corrected PET
data are used
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– Chest: T2-weighted turbo spin echo, transverse,
respiratory-triggered
– Abdomen: volume interpolated breathhold exami-
nation (VIBE) gradient echo sequence (e.g. VIBE
dynamic, three phases after contrast agent adminis-
tration) and a 2-D T1-weighted fast spoiled gradient
echo sequence (e.g. FLASH 2-D, respiratory-
triggered)
– Pelvis: T1-weighted spin echo with fat saturation,
transverse
Concerning our PET/MR imaging in children, with re-
gard to the MR sequences, the following experiences are
worth mentioning:
1. T2-weighted TIRM sequences are superior to spectral
fat saturation, as the fat saturation and the shim process
are more stable.
2. T1-weighted gradient echo sequences are used in the
abdominal region due to a preferred shorter acquisition
time, sometimes even only as a complementary T1-
weighted VIBE sequence.
3. The average number of acquisitions can be reduced
because of the high field strength; owing to the high
field strength parallel imaging in most locations is pos-
sible and necessary.
4. All sequences in the thoracic region and upper abdomen
were performed exclusively with respiratory triggering.
In our experience, a respiratory belt is much more stable
than navigator sequences in children, since the mean
position of the diaphragm changes frequently during the
lengthy examination. The repetition time for T2-
weighted sequences should be minimized (typically
2,000 ms), which on the one hand leads to a significant-
ly shorter examination time and on the other hand is
more suitable for the faster breathing cycle of young
children at 25–30 breaths per minute [18].
Patient preparation, FDG dose and the PET acquisition
protocol follow the guidelines of the European and German
societies of nuclear medicine for FDG PET examinations in
children [11, 19]. Imaging started 70 ±15 min after intrave-
nous FDG administration. Doses were in the range 42–
371 MBq depending on body weight. Images covered the
patient from the head to the middle of the upper legs and
generally involved seven bed positions.
Preliminary findings
Using the Siemens mMR scanner, a total of 21 FDG PET/
MR scans were carried out in 15 children (12 boys, 3 girls)
between November 2011 and July 2012. The children’s ages
ranged from 1 year 11 months to 16 years 8 months (mean
age: 10 years 7 months). Oncological diseases included non-
Hodgkin lymphoma (n04), Hodgkin lymphoma (n03),





Distance factor (%) 10 0
Image orientation Coronal Transverse
Phase-encoding direction Feet→ head Anterior→ posterior
Phase oversampling 50 10
Inversion time (ms) 220 220
Field of view 500 mm Patient-adapted
Phase field of view (%) 50 70
Slice thickness (mm) 5 4.5
Repetition time (ms) 2,090 2,000
Echo time (ms) 47 48
Number of averages 1 1
Flip angle (°) 150 133
Base resolution 320 384
Phase resolution (%) 75 75
Parallel acquisition technique GRAPPA 2 GRAPPA 2
Turbo factor 16 16
Voxel size 2.1×1.6×5 1.7×1.3×4.5
Time per stack (min) 1:08 1:32
Stacks/bed position 7 7
Data acquisition time with
respiratory triggering (min, approx)
15 25
Table 2 Number of involved
sites and tumour stage (Ann
Arbor-classification) diagnosed
with the PET component, the
MRI component and by com-
bined PET/MR
Patient Histology Involved sites Stage
PET MRI PET MRI Final
1 Classic Hodgkin lymphoma 7 5 II II II
2 Classic Hodgkin lymphoma 7 6 II II II
3 Lymphocyte-predominant Hodgkin lymphoma 2 1 II I II
4 Burkitt lymphoma 5 3 II III II
5 T-cell non-Hodgkin lymphoma 5 9 IV IV IV
6 T-cell non-Hodgkin lymphoma 10 8 IV IV IV
Pediatr Radiol (2013) 43:860–875 863
neuroblastoma (n02), primitive neuroectodermal tumour
(n01), Ewing sarcoma (n01), soft tissue sarcoma (n02),
acute myeloid leukaemia with extramedullary manifestation
(n01) and metastasized germ cell tumour of the testis (n01).
Ten of the children were investigated before the start of
systemic treatment for initial staging. Responses to treat-
ment were assessed in 11 PET/MR investigations.
The technical success rate was 100%. This relates to the
successful and simultaneous acquisition of MR and PET data.
Clear advantages of PET/MR over PET/CTand additionalMRI
are the lower radiation dose and the reduced number of inves-
tigations in the children, decreasing the psychological stress and
the length of the diagnostic period before the start of treatment.
Any additional diagnostic impacts of synchronous PET/MR
need to be clarified in future studies. However, in comparison
to the use of PET/CTalone, PET/MR has advantages, especial-
ly in the description of the anatomical details of primary
tumours due to the higher soft tissue contrast of MR imaging.
In the first months of clinical use, PET/MR led to con-
siderable simplification of the practical course of action in
children with multifocal oncological diseases. The diagnos-
tic process generally required only one examination (maxi-
mum two), which was significantly more acceptable to the
children than previous sequential diagnostic procedures.
Previous sequential procedures included a local MR scan,
a PET or a PET/CT scan, normally a whole-body MR scan
and sometimes a thoracic CT scan. This improvement in
workflow led to a real one-stop-shop diagnostic procedure
Fig. 2 A 13-year-old boy with Hodgkin disease stage II. a Involve-
ment of both sides of the submandibular, cervical, and upper and
middle mediastinum (arrows). b Involvement of the submandibular
lymph nodes (arrows) was not positively identified on MR criteria
(size), but the PET image shows significantly enhanced FDG uptake.
Arrows indicate positive PET/MR findings
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Fig. 2 (continued)
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that replaced the previous multiple examinations. PET/MR
produces only partially redundant, but more commonly ad-
ditive, information. These results were elucidated in a joint
findings discussion between radiologists and nuclear physi-
cians, and then communicated in a joint findings report to
clinical colleagues. A particularly positive visual impact was
observed when the pathological findings were demonstrated
to treating physicians on presentation of the fused images
combining the hyperintensity shown by MR and the colour-
coded metabolic hyperactivity shown by PET.
Fig. 3 A 2.5-year-old boy with bilateral cervical (arrows) Burkitt lymphoma. Arrows indicate positive PET/MR findings
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Lymphomas in children
Six children have been investigated for initial staging of
lymphoma (including Hodgkin lymphoma, Burkitt lympho-
ma and T-cell lymphoma; Table 2).
PET and MR components concordantly detected 25
tumour-involved areas. PET detected 10 more metabolically
active lymph node areas, and MRI showed three addition-
ally involved organs in one child (Fig. 4) and two additional
lymph node sites suspicious for tumour. In two of the six
Fig. 4 An 11-year-old boy with T-cell lymphoma with involvement of
the neck, mediastinum, kidneys and bone marrow. a Significantly in-
creased glucose metabolism of the pleural effusion also indicates tumour
involvement in this region, while on MR this effusion was interpreted as
an expression of congestion due to the large mediastinal tumour mass
(arrows). bNote the significant pathological structure, size and metabolic
activity (encircled, arrows) of the kidneys and the bone marrow in the left
proximal femur. c The additional findings shown by the whole-body
diffusion-weighted image (left column) and ADC map (middle column)
show, concordant with PET findings, a distinct diffusion disorder in the
area of the mediastinal mass (top row, arrow), the left kidney (middle row,
arrow), and the proximal left femur (bottom row, arrow). Because of the
bilateral similarity of the changes in the kidney, the interpretation of the
PETscanwas less certain. On the basis of significantly restricted diffusion
and scale, the MR scan with diffusion-weighted image provided more
conclusive identification of an active tumour tissue. Arrows in Fig. 4a and
4b indicate positive PET/MR findings. Arrows in Fig. 4c indicate positive
ADC value typical for tumour tissue
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children, the tumour restaged by joint interpretation of PET/
MR. One child with lymphocyte-predominant Hodgkin
lymphoma had histologically confirmed involvement of
the left inguinal nodes. However, PET also showed en-
hanced FDG uptake suspicious for tumour in the right
inguinal nodes of borderline size, thus upstaging the child
from stage I to stage II. In a child with Burkitt lymphoma,
MR detected a 2.3-mm inguinal lymph node. Due to normal
glucose uptake on PET, this node was considered not in-
volved and the child was assigned to stage II.
Thus, the PET component proved to be appropriate and
helpful for the detection of involved lymph nodes that were
morphologically of borderline size but which on PET showed
increased glucose metabolism, and for the characterization of
slightly enlarged, but not involved, lymph nodes due to
normal glucose metabolism (Figs. 2 and 3) [20]. In contrast,
in the children studied, the MR examination demonstrated an
advantage in those with symmetrical involvement of organs,
as demonstrated by the example of a child with involvement
of the testes (not shown) and the kidneys (Fig. 4). Because of
the bilateral characteristics, the PETscan produced differential
diagnostic uncertainties in the interpretation of these findings.
In addition, PET/MR provides options for whole-body
diffusion imaging with B-values from 800 to 1,000, provid-
ing in individual cases an additional aid for differential
diagnosis if the PET and MR findings produce differing
interpretations [21]. Restricted diffusivity suggests in-
creased cellularity and also a change in the nuclear–cyto-
plasmic ratio, and therefore suggests the possibility of
metabolically active tumour tissue [22, 23].
Fig. 4 (continued)
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Solid child-like tumours
Even in solid tumours, the establishment of the metastasis and
lymph node status using PET/MR is faster and clearer than
with an isolated whole-body MR. In contrast, local staging,
because of the spatial resolution required, is still the domain of
dedicated MR imaging. Using the sequence protocols de-
scribed above, we were able to reach a compromise, which
in particular offered sufficient anatomical orientation for the
paediatric surgeon, but nevertheless still embraced the concept
of a one-stop-shop examination. The visually impressive fu-
sion of high-resolution anatomy and metabolic activity was
very positively rated by clinical colleagues. Because big
tumours often exhibit large variability in local glucose uptake,
the synergy of the twomethods is obvious and can be used, for
example, for the determination of the biopsy site and for
treatment planning (Figs. 5 and 6).
FDG uptake may vary especially in neuroblastoma, and
may diverge from more specific metaiodobenzylguanidine
(MIBG) uptake labelling chromaffin tissues [24]. Since the
intensity of FDG uptake in neuroblastoma is an adverse
prognostic marker, FDG PET should be used in addition to
MR and MIBG scintigraphy for the initial evaluation of
high-risk neuroblastomas [25]. Small metastases (e.g. in
the liver and lungs) usually show a concordant finding.
Thus, in a child with a pulmonary metastasis that was only
3 mm in size, both methods were concordant, allowing a
confident identification (Fig. 5). However, in the immediate
future, lung CT will keep its place in the initial stages as a
necessary supplementary modality during the transitional
and evaluation phases. In most paediatric oncology proto-
cols, lung CT scans are mandatory; only clear positive
evidence from PET/MR will lead to a protocol change.
Evaluation of treatment response and follow-up
Because of the novelty of PET/MR, we can at present only
report follow-up studies in children in whom the initial PET/
CT and MR investigations were performed consecutively.
As shown in Fig. 7, lymphoma involvement of the ilium,
initially demonstrated by PET/CT, was shown by PET to
have normalized following chemotherapy, demonstrating an
adequate treatment response. In contrast, MR imaging
showed that a residual tumour mass was still present. In a
Fig. 4 (continued)
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child with thoracic primitive neuroectodermal tumour, PET
during therapy showed that metabolically active tumour
tissue remained in the periphery, while no reliable state-
ments could be made following MR (Fig. 8). In a child with
a history of metastatic extraosseous Ewing sarcoma, isolated
PET findings indicated tumour recurrence, while the MR
findings, on the basis of morphology and in comparison to a
previous MR scan, indicated an inflammatory process
(Fig. 9). The latter was confirmed histologically.
These examples illustrate that, as a rule, following che-
motherapy, the metabolic reaction generally occurs sooner
and more completely than the morphological reaction [26].
Therefore, for these therapeutic indications, PET is superior
to MR alone. For the evaluation and localization of PET-
Fig. 5 A 15-year-old boy with left testicular tumour with left retro-
peritoneal, supraclavicular and hepatic metastases (arrows). a The
primary tumour in the left testicle and the retroperitoneal metastasis
exhibit a very inhomogeneous enhancement of the glucose metabolism
with larger metabolically inactive areas showing no enhancement. This
can only be explained in part by tumour necrosis. The liver metastasis
shows significantly enhanced glucose uptake. b A small metastasis
(3 mm, arrow) in the left lung was diagnosed with good respiratory
triggering by MR and by PET. This indicates that the system operates
with high performance and yields superior images even of very small
lesions. Arrows indicate positive PET/MR findings
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Fig. 6 A 2-year-old boy with a large abdominal neuroblastoma that
emanates from the sympathetic chain. Top row: the tumour (arrows) is
growing into the spinal canal and involves the fourth and fifth lumbar
vertebrae. The highly differentiated tumour shows only slightly intense
inhomogeneous FDG uptake. Lower row: transaxial slices show multiple
(arrows) lung metastases and pleural metastases. The metastases are seen
on the concordant respiratory-triggered T2-weighted TIRM images (a) and
on the PET images (b, c); smaller metastases of 3–5 mm are clearly shown
on the MR images. Arrows indicate positive PET/MR findings
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positive residual findings, however, exact delineation of the
anatomy at the same time is of great value. Regarding this
issue, the complementary information given by PET/MR
will be of increasing importance in the future [27].
Limitations and pitfalls in PET/MR
In spite of the good overall image quality of both the MR and
the PET components achieved with the acquisition protocol
Fig. 7 Anaplastic lymphoma
with involvement of the ilium.
Top row: initial, decisive MR
image (a) and PET/CT image
(arrow) (b). Bottom row: after
treatment. In the whole-body
MRI, residual bone lesions
(arrows) can still be seen (a),
which are not positive on the
PET image (arrow) (b), and
thus would be considered as
inactive residual tissue
Fig. 8 Large right-sided thoracic primitive neuroectodermal tumour
residuum (arrow) in a 13-year-old boy at the end of neoadjuvant
chemotherapy. The dark tumour on the T2-weighted MR image and
mostly unenhanced FDG uptake on the PET image argue for predom-
inant fibrous components. This was confirmed later histologically
(Salzer-Kuntschik grade 2). However, in the cranial portion of the
tumour there is a narrow zone of increased FDG uptake. On MRI,
the still active residual tumour tissue was only ambiguously identified.
Arrow indicates positive PET/MR finding
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presented and the high technical success rate, several limitations
have to be addressed. The typical limitations of whole-body
MR persist even with PET/MR; for example, signal inhomo-
geneity was sometimes found in overlapping regions of theMR
sections. Another critical factor was the calculation of the μ-
map by means of the Dixon sequence [9]. Here we found
inaccurate water/fat allocation in certain bed positions in five
cases, which could have led to incorrect attenuation correction
of the PET data. Whether this reduced the diagnostic value of
the PET data in comparison to the PET/CT data cannot be
assessed at this stage.
It is not yet possible to characterize the diagnostic accu-
racy of PET/MR. The aim of this paper is to share our first
experience and to propose the first acquisition protocol for
Fig. 9 A 13-year-old boy with a history of extraosseous metastatic
Ewing sarcoma of the pelvis now showing new imaging findings
(arrows) suspicious for soft tissue metastasis in the adductor longus
muscle. On MR imaging, size regression was seen within 7 weeks.
Because of an intensive increase in glucose utilization, a biopsy was
performed, which revealed inflammatory changes. Arrows indicate the
positive PET/MR finding
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use in children. The scientific evaluation of PET/MR must
now be the subject of prospective studies preferably with a
multicentre design.
Another limitation of PET/MR is the huge amount of data
produced by the Dixon sequence, the whole-body MR
images and the PET data (approximately 2,800 images in
total). Therefore, it is not possible to demonstrate a PET/MR
study on a normal PACS workstation, even if the composite
series only are transferred onto the PACS. The current
version of syngo.via for PET/MR (Siemens, Erlangen, Ger-
many) does not solve these problems sufficiently. Image
transfer to the referring physician using a web application
is no longer possible with the current web-based viewer
solutions. So improved software solutions are required.
The main limitation of PET/MR, however, is the duration
of the whole-body MR protocol. Due to respiratory trigger-
ing in the imaging of the thorax and upper abdomen, an
ordinary MR acquisition lasts 45 min. Additional sequences
for dedicated local diagnosis require a further 20–30 min.
Normally, we allow the patient a period of rest away from
the unit between these two parts of the study. Children under
6 years of age need anaesthesiological support.
Conclusion
In children, minimizing the radiation dose is a consideration
that determines the choice of imaging modality. With the
introduction of PET/MR, the CT exposure component previ-
ously accrued in PET/CT studies can be eliminated [28]. In
this way, the radiation exposure from a single hybrid imaging
scan is reduced by around 80%, to only one effective dose of
4.6 mSv (two yearly doses of natural radiation exposure) [13].
The clinical advantages of PET/MR in children with
oncological diseases above all rest in the significantly great-
er value that the MR component offers compared to con-
ventional CT. MR is capable of identifying the anatomy,
perfusion and diffusion of a tumour [29]. In addition, the
soft-tissue resolution of MR is clearly superior to that of CT
[30]. The simultaneously measured PET signal provides the
established advantages of function determination and quan-
tification by means of SUV [31–33].
Our initial experience in children suffering from mul-
tifocal, oncological diseases shows that a complete PET/
MR examination that is completed within 60 min pro-
vides all relevant information for paediatric surgeons
and paediatric oncologists. As a result, the reduction
in time required for the diagnostic procedure in the
initial stages is relevant. All of these established advan-
tages show that in children with oncological diseases
combined PET/MR including whole-body diffusion
weighting demonstrates a new quality in imaging and
functional diagnostics [34].
Open Access This article is distributed under the terms of the Creative
Commons Attribution License, which permits any use, distribution,
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